

# Paul Glue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5891591/publications.pdf>

Version: 2024-02-01

180  
papers

6,773  
citations

61977  
43  
h-index

76898  
74  
g-index

180  
all docs

180  
docs citations

180  
times ranked

5785  
citing authors

#	ARTICLE	IF	CITATIONS
1	Possible mechanisms for treatment heterogeneity in clinical trials of adjunctive Nâ€acetylcysteine for bipolar depression. Bipolar Disorders, 2022, 24, 213-213.	1.9	0
2	Use of advance directives to promote supported decision-making in mental health care: Implications of international trends for reform in New Zealand. Australian and New Zealand Journal of Psychiatry, 2022, , 000486742210792.	2.3	0
3	Is There Evidence for the Specificity of Closed-Loop Brain Training in the Treatment of Internalizing Disorders? A Systematic Review. Frontiers in Neuroscience, 2022, 16, 821136.	2.8	0
4	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatmentâ€Refractory Depression. Clinical Pharmacology and Therapeutics, 2022, 112, 720-729.	4.7	5
5	The Great Escape. Centenariansâ€™ exceptional health. Aging Clinical and Experimental Research, 2021, 33, 513-520.	2.9	4
6	Influence of formulation and route of administration on ketamineâ€™s safety and tolerability: systematic review. European Journal of Clinical Pharmacology, 2021, 77, 671-676.	1.9	8
7	Internalize at your peril: internalizing disorders as risk factors for dementiaâ€™ cohort study. GeroScience, 2021, 43, 253-261.	4.6	3
8	Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology, 2021, 35, 137-141.	4.0	6
9	Help and Hindrances to Completion of Psychiatric Advance Directives. Psychiatric Services, 2021, 72, 216-218.	2.0	8
10	Olfactory shifts linked to postpartum depression. Scientific Reports, 2021, 11, 14947.	3.3	4
11	Right frontal anxiolytic-sensitive EEG â€thetaâ€™ rhythm in the stop-signal task is a theory-based anxiety disorder biomarker. Scientific Reports, 2021, 11, 19746.	3.3	15
12	Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110567.	2.7	20
13	Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 2020, 34, 267-272.	4.0	40
14	Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 2020, 266, 615-620.	4.1	28
15	Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders. Personality Neuroscience, 2020, 3, e2.	1.6	10
16	Ageing badly: indicators of old-age structure in Australia and New Zealand. Journal of Primary Health Care, 2020, 12, 272.	0.6	5
17	Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532092247.	2.7	19
18	The content of Mental Health Advance Preference statements (MAPs): An assessment of completed advance directives in one New Zealand health board. International Journal of Law and Psychiatry, 2020, 68, 101537.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Aberrant salience and reward processing: a comparison of measures in schizophrenia and anxiety. <i>Psychological Medicine</i> , 2020, 51, 1-9.	4.5	10
20	Ascendingâ€Dose Study of Controlledâ€Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 751-757.	2.0	7
21	Fatigue, sleep and depression: An exploratory interRAI study of older adults.. <i>Psychiatry Research</i> , 2020, 284, 112772.	3.3	8
22	Anterior Cingulate Cortex Implants for Alcohol Addiction: A Feasibility Study. <i>Neurotherapeutics</i> , 2020, 17, 1287-1299.	4.4	12
23	Progesterone loading as a strategy for treating postpartum depression. <i>Human Psychopharmacology</i> , 2020, 35, e2731.	1.5	8
24	Human anxiety-specific â€œthetaâ€ occurs with selective stopping and localizes to right inferior frontal gyrus.. <i>Behavioral Neuroscience</i> , 2020, 134, 547-555.	1.2	9
25	Advance Directives: Another Gap in Services for People With Borderline Personality Disorder. <i>Psychiatric Services</i> , 2020, 71, 528-529.	2.0	2
26	The clinical toxicology of cannabis. <i>New Zealand Medical Journal</i> , 2020, 133, 96-103.	0.5	1
27	Service user, whānau and peer support workersâ€™ perceptions of advance directives for mental health. <i>International Journal of Mental Health Nursing</i> , 2019, 28, 1296-1305.	3.8	10
28	Screaming behaviour in response to electroconvulsive treatment: psychogeriatric note on a patient with Alzheimer's disease. <i>Psychogeriatrics</i> , 2019, 19, 626-627.	1.2	1
29	A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression â€œ the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 260-261.	4.0	0
30	Low-risk and high-risk groups matter in suicide risk. <i>Psychological Medicine</i> , 2019, 49, 879-880.	4.5	0
31	Dissociation after ketamine dosing: Is the CADSS fit for purpose?. <i>Journal of Affective Disorders</i> , 2019, 244, 239-240.	4.1	6
32	Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients. <i>EBioMedicine</i> , 2018, 27, 134-137.	6.1	10
33	Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. <i>Drug Delivery and Translational Research</i> , 2018, 8, 780-786.	5.8	17
34	Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 717-724.	2.1	26
35	Repeated intranasal ketamine for treatment-resistant depression â€œ the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2018, 32, 397-407.	4.0	66
36	Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. <i>Journal of Psychopharmacology</i> , 2018, 32, 663-667.	4.0	58

#	ARTICLE	IF	CITATIONS
37	Comparison of Psychosocial Variables Associated With Loneliness in Centenarian vs Elderly Populations in New Zealand. JAMA Network Open, 2018, 1, e183880.	5.9	20
38	The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats. Journal of Psychopharmacology, 2018, 32, 1127-1132.	4.0	8
39	How comprehensive is suicide risk assessment in the emergency department?. New Zealand Medical Journal, 2018, 131, 11-13.	0.5	0
40	A MAP to mental health: the process of creating a collaborative advance preferences instrument. New Zealand Medical Journal, 2018, 131, 18-26.	0.5	6
41	Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. World Journal of Biological Psychiatry, 2017, 18, 489-489.	2.6	2
42	Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 2017, 31, 1302-1305.	4.0	83
43	Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. American Journal of Geriatric Psychiatry, 2017, 25, 1199-1209.	1.2	85
44	Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 2017, 31, 1306-1311.	4.0	16
45	Ketamine and Suicidal Ideation. Journal of Clinical Psychopharmacology, 2017, 37, 282-283.	1.4	3
46	Anterior Cingulate Implant for Obsessive-Compulsive Disorder. World Neurosurgery, 2017, 97, 754.e7-754.e16.	1.3	19
47	Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics. Journal of Clinical Pharmacology, 2016, 56, 960-965.	2.0	11
48	Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 2016, 134, 48-56.	4.5	160
49	Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology, 2016, 189, 10-13.	4.1	23
50	Adjunctive pregabalin vs gabapentin for focal seizures. Neurology, 2016, 87, 1242-1249.	1.1	17
51	Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. Australasian Psychiatry, 2016, 24, 598-601.	0.7	42
52	Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. Clinical Pharmacology in Drug Development, 2016, 5, 460-468.	1.6	30
53	Psychosurgery Reduces Uncertainty and Increases Free Will? A Review. Neuromodulation, 2016, 19, 239-248.	0.8	40
54	Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus. Biological Psychology, 2016, 117, 50-55.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv124.	2.1	175
56	Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. New Zealand Medical Journal, 2016, 129, 37-40.	0.5	0
57	Psychiatric assessment is a necessary part of humane care. BMJ, The, 2015, 351, h4315.	6.0	0
58	An improved human anxiety process biomarker: characterization of frequency band, personality and pharmacology. Translational Psychiatry, 2015, 5, e699-e699.	4.8	28
59	Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1215-1220.	2.3	24
60	Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 2015, 55, 189-194.	2.0	43
61	Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20µmg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 2015, 55, 680-687.	2.0	28
62	Why academic psychiatry is endangered. Australian and New Zealand Journal of Psychiatry, 2015, 49, 9-12.	2.3	25
63	Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids. New Zealand Medical Journal, 2015, 128, 15-8.	0.5	22
64	Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. Drug Discoveries and Therapeutics, 2014, 8, 89-95.	1.5	12
65	“Violence is Not Part of Our Job”: A Thematic Analysis of Psychiatric Mental Health Nurses’ Experiences of Patient Assaults from a New Zealand Perspective. Issues in Mental Health Nursing, 2014, 35, 647-655.	1.2	69
66	When the mandatory second opinion fails to approve compulsory treatment. Australasian Psychiatry, 2014, 22, 337-340.	0.7	1
67	Electroconvulsive therapy use in Otago, New Zealand: a 10-year retrospective audit of patient-level treatment data. Australian and New Zealand Journal of Psychiatry, 2014, 48, 548-553.	2.3	3
68	Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World Journal of Biological Psychiatry, 2014, 15, 579-584.	2.6	70
69	Long-Lasting Effects of a Single Subcutaneous Dose of Ketamine for Treating Melancholic Depression: A Case Report. Biological Psychiatry, 2014, 76, e1-e2.	1.3	32
70	Oxytocin improves emotion recognition for older males. Neurobiology of Aging, 2014, 35, 2246-2248.	3.1	49
71	Impact of Dietary Benzoic Acid on Treatment Response in Schizophrenia. JAMA Psychiatry, 2014, 71, 1298.	11.0	1
72	Postgraduation retention of medical students from Otago and Auckland medical programmes. New Zealand Medical Journal, 2014, 127, 47-54.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Influence of rural background and rural medical training on postgraduate medical training and location in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 12-6.	0.5	2
74	Systematic review of cognitive development across childhood in Down syndrome: implications for treatment interventions. <i>Journal of Intellectual Disability Research</i> , 2013, 57, 306-318.	2.0	64
75	Anti-anxiety drugs reduce conflict-specific $\alpha$ -theta A possible human anxiety-specific biomarker. <i>Journal of Affective Disorders</i> , 2013, 148, 104-111.	4.1	47
76	Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 710-727.	2.3	100
77	Quantification of Brain Voriconazole Levels in Healthy Adults Using Fluorine Magnetic Resonance Spectroscopy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5271-5276.	3.2	18
78	Case Report: Long-Term Mood Response To Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer. <i>Journal of Palliative Medicine</i> , 2013, 16, 719-720.	1.1	15
79	Hospitalisation associated with use of the synthetic cannabinoid K2. <i>New Zealand Medical Journal</i> , 2013, 126, 18-23.	0.5	29
80	Mood and Pain Responses to Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer. <i>Journal of Palliative Medicine</i> , 2012, 15, 400-403.	1.1	42
81	Comparative efficacy of anti-manic drugs in acute mania. <i>Lancet, The</i> , 2012, 379, 892.	13.7	1
82	Evaluation of Bioequivalence Between Clozapine Suspension and Tablet Formulations. <i>Clinical Drug Investigation</i> , 2012, 32, 723-727.	2.2	13
83	Benzodiazepines for generalised anxiety disorder (GAD). <i>The Cochrane Library</i> , 2012, , .	2.8	1
84	Optimal treatment of social phobia: systematic review and meta-analysis. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 203.	2.2	55
85	Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 415-418.	1.9	19
86	Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 229-236.	2.0	92
87	Dose- and Exposure-Response to Ketamine in Depression. <i>Biological Psychiatry</i> , 2011, 70, e9-e10.	1.3	42
88	Switching from Quetiapine to Ziprasidone. <i>Journal of Psychiatric Practice</i> , 2011, 17, 100-109.	0.7	15
89	Study design and patient characteristics and outcome in acute mania clinical trials. <i>Bipolar Disorders</i> , 2011, 13, 125-132.	1.9	11
90	Comparison of pharmacokinetic variability of fesoterodine <i>vs.</i> tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 226-234.	2.4	24

#	ARTICLE	IF	CITATIONS
91	Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania – A systematic review and meta-analysis. Journal of Affective Disorders, 2011, 134, 14-19.	4.1	27
92	An Eight-Week Trial Investigating the Efficacy and Tolerability of Atorvastatin for Children and Adolescents With Heterozygous Familial Hypercholesterolemia. Pediatric Cardiology, 2011, 32, 433-441.	1.3	25
93	Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function. Journal of Clinical Pharmacology, 2011, 51, 731-738.	2.0	7
94	Off-label use of quetiapine in New Zealand—a cause for concern?. New Zealand Medical Journal, 2011, 124, 10-3.	0.5	3
95	New Prospects for the Drug Treatment of Generalized Anxiety Disorder – A Systematic Review. Current Drug Therapy, 2010, 5, 86-94.	0.3	2
96	The pharmacokinetic profile of fesoterodine 8Âmg with daytime or nighttime dosing. European Journal of Clinical Pharmacology, 2010, 66, 171-176.	1.9	13
97	Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – A meta-analysis. Journal of Affective Disorders, 2010, 123, 9-16.	4.1	59
98	Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. British Journal of Clinical Pharmacology, 2010, 69, 51-57.	2.4	28
99	Pregabalin for painful HIV neuropathy. Neurology, 2010, 74, 413-420.	1.1	185
100	Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders. Australian and New Zealand Journal of Psychiatry, 2010, 44, 697-705.	2.3	83
101	Considerations for the Design and Conduct of a Pharmacovigilance Study Involving Mass Drug Administration in a Resource-Constrained Setting. PLoS Neglected Tropical Diseases, 2010, 4, e564.	3.0	4
102	Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study. Journal of Clinical Pharmacology, 2009, 49, 291-300.	2.0	18
103	Can Drug Treatments Enhance Learning in Subjects with Intellectual Disability?. Australian and New Zealand Journal of Psychiatry, 2009, 43, 899-904.	2.3	6
104	A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Medical Research Methodology, 2009, 9, 55.	3.1	54
105	Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. British Journal of Clinical Pharmacology, 2009, 68, 682-689.	2.4	9
106	Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophrenia Research, 2009, 111, 39-45.	2.0	15
107	The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption. Journal of Clinical Psychiatry, 2009, 70, 58-62.	2.2	45
108	Response to – Feedback to Tolterodine QT – Clinical Pharmacology and Therapeutics, 2008, 83, 233-233.	4.7	1



#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. British Journal of Clinical Pharmacology, 2008, 65, 531-539.	2.4	40
110	Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. British Journal of Clinical Pharmacology, 2008, 65, 523-530.	2.4	32
111	The Effect of Azithromycin on Ivermectin Pharmacokinetics—A Population Pharmacokinetic Model Analysis. PLoS Neglected Tropical Diseases, 2008, 2, e236.	3.0	32
112	Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial*. Critical Care Medicine, 2007, 35, 1863-1868.	0.9	28
113	Thorough QT Study with Recommended and Supratherapeutic Doses of Tolterodine. Clinical Pharmacology and Therapeutics, 2007, 81, 377-385.	4.7	81
114	Model-based Drug Development. Clinical Pharmacology and Therapeutics, 2007, 82, 21-32.	4.7	394
115	PHARMACOKINETICS OF AZITHROMYCIN AND THE COMBINATION OF IVERMECTIN AND ALBENDAZOLE WHEN ADMINISTERED ALONE AND CONCURRENTLY IN HEALTHY VOLUNTEERS. American Journal of Tropical Medicine and Hygiene, 2007, 76, 1153-1157.	1.4	33
116	Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. American Journal of Tropical Medicine and Hygiene, 2007, 76, 1153-7.	1.4	20
117	The effect of food on the absorption of oral ziprasidone. Psychopharmacology Bulletin, 2007, 40, 58-68.	0.0	27
118	Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet. Journal of Clinical Pharmacology, 2006, 46, 1030-1037.	2.0	25
119	Effect of Food on the Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet. Journal of Clinical Pharmacology, 2006, 46, 1212-1216.	2.0	25
120	Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers. American Journal of Therapeutics, 2006, 13, 418-422.	0.9	19
121	Bioavailability of Amlodipine Besylate Following Oral Administration as a Tablet Dispersed in Applesauce. Journal of Clinical Pharmacology, 2005, 45, 695-698.	2.0	5
122	Single-dose pharmacokinetics and tolerability of pegylated interferon- $\beta$ 2b in young and elderly healthy subjects. British Journal of Clinical Pharmacology, 2003, 56, 131-134.	2.4	26
123	Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models. Clinical Pharmacology and Therapeutics, 2002, 72, 349-361.	4.7	48
124	Single-Dose Pharmacokinetics and Safety of Pegylated Interferon- $\beta$ 2b in Patients with Chronic Renal Dysfunction. Journal of Clinical Pharmacology, 2002, 42, 1109-1115.	2.0	74
125	Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrology Dialysis Transplantation, 2001, 16, 193-195.	0.7	100
126	Population pharmacokinetic analysis of pegylated interferon alfa- $\beta$ 2b and interferon alfa- $\beta$ 2b in patients with chronic hepatitis C. Clinical Pharmacology and Therapeutics, 2001, 69, 407-421.	4.7	42



#	ARTICLE	IF	CITATIONS
127	Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C. Therapeutic Drug Monitoring, 2000, 22, 555-565.	2.0	163
128	The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. British Journal of Clinical Pharmacology, 2000, 49, 417-421.	2.4	38
129	A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C. Hepatology, 2000, 32, 647-653.	7.3	234
130	Pegylated interferon- $\alpha$ 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clinical Pharmacology and Therapeutics, 2000, 68, 556-567.	4.7	452
131	Pharmacokinetics and Absolute Bioavailability of Ribavirin in Healthy Volunteers as Determined by Stable-Isotope Methodology. Antimicrobial Agents and Chemotherapy, 1999, 43, 2451-2456.	3.2	98
132	Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment. Cellular and Molecular Neurobiology, 1999, 19, 309-323.	3.3	55
133	Changes in Serum Hepatitis C Virus RNA in Interferon Nonresponders Retreated With Interferon Plus Ribavirin. Journal of Clinical Gastroenterology, 1999, 28, 313-316.	2.2	11
134	The clinical pharmacology of ribavirin. Seminars in Liver Disease, 1999, 19 Suppl 1, 17-24.	3.6	71
135	Intestinal absorption of ribavirin is preferentially mediated by the Na <sup>+</sup> -nucleoside purine (N1) transporter. Pharmaceutical Research, 1998, 15, 950-952.	3.5	79
136	Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	5.4	124
137	Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. British Journal of Clinical Pharmacology, 1998, 46, 563-570.	2.4	133
138	Pharmacokinetic Interactions with Felbamate. Clinical Pharmacokinetics, 1997, 33, 214-224.	3.5	57
139	Effect of Felbamate on the Pharmacokinetics of Lamotrigine. Journal of Clinical Pharmacology, 1996, 36, 634-638.	2.0	22
140	Effect of Felbamate on Valproic Acid Disposition in Healthy Volunteers: Inhibition of beta-Oxidation. Epilepsia, 1996, 37, 91-97.	5.1	56
141	Psychiatry, psychopharmacology and P-450s. Human Psychopharmacology, 1996, 11, 97-114.	1.5	36
142	Pharmacodynamic Effects of Interferon ALFA-2b in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 1996, 59, 205-205.	4.7	1
143	The Effect of Age on the Apparent Clearance of Felbamate: A Retrospective Analysis Using Nonlinear Mixed-Effects Modeling. Therapeutic Drug Monitoring, 1996, 18, 19-29.	2.0	27
144	Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clinical Pharmacology and Therapeutics, 1995, 58, 383-389.	4.7	28

#	ARTICLE	IF	CITATIONS
145	Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 523-531.	4.7	87
146	Effects of felbamate on the pharmacokinetics of phenobarbital. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 279-287.	4.7	62
147	The relationship between benzodiazepine receptor sensitivity and neuroticism. <i>Journal of Anxiety Disorders</i> , 1995, 9, 33-45.	3.2	23
148	Saccadic eye movement parameters in normal subjects. <i>Electroencephalography and Clinical Neurophysiology</i> , 1993, 86, 69-74.	0.3	65
149	Challenge tests: Assessment of the noradrenergic and gaba systems in depression and anxiety disorders. <i>Molecular Aspects of Medicine</i> , 1992, 13, 221-247.	6.4	18
150	Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: Preliminary open trial of the effects of acute and chronic idazoxan. <i>Psychoneuroendocrinology</i> , 1992, 17, 261-266.	2.7	7
151	Flumazenil and saccadic eye movements in patients with panic disorder and normal controls. <i>Human Psychopharmacology</i> , 1992, 7, 45-50.	1.5	7
152	Benzodiazepine receptor sensitivity in panic disorder. <i>Lancet</i> , The, 1991, 337, 563.	13.7	6
153	Pharmacology of saccadic eye movements in man. <i>Psychopharmacology</i> , 1991, 105, 368-373.	3.1	34
154	Irritability in panic disorder: Effects of imipramine treatment. <i>Human Psychopharmacology</i> , 1991, 6, 49-52.	1.5	3
155	Pharmacology of saccadic eye movements in man. <i>Psychopharmacology</i> , 1991, 105, 361-367.	3.1	83
156	Merck, Sharp & Dohme Prize for Young Psychopharmacologists. <i>Journal of Psychopharmacology</i> , 1991, 5, 377-387.	4.0	35
157	Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. <i>Journal of Psychopharmacology</i> , 1991, 5, 396-403.	4.0	17
158	Overexcitement and Disinhibition. <i>British Journal of Psychiatry</i> , 1990, 157, 491-499.	2.8	84
159	Regional neurotransmitter responses after acute and chronic electroconvulsive shock. <i>Psychopharmacology</i> , 1990, 100, 60-65.	3.1	51
160	Lithium Treatment Effect on Serotonin Function. <i>Archives of General Psychiatry</i> , 1990, 47, 289.	12.3	1
161	Flumazenil Provocation of Panic Attacks. <i>Archives of General Psychiatry</i> , 1990, 47, 917.	12.3	261
162	Neuropharmacological and Clinical Aspects of Alcohol Withdrawal. <i>Annals of Medicine</i> , 1990, 22, 275-281.	3.8	26

#	ARTICLE	IF	CITATIONS
163	Oxytocin and vasopressin responses to ECT. <i>Psychiatry Research</i> , 1990, 32, 201-202.	3.3	11
164	Lactate-induced electrolyte changes in the cerebrospinal fluid of rabbits. <i>Biological Psychiatry</i> , 1990, 27, 104-108.	1.3	6
165	Neurochemical insights into alcohol kindling. <i>Human Psychopharmacology</i> , 1989, 4, 157-158.	1.5	3
166	Studies of Alpha-2-Adrenoceptor Function in Abstinent Alcoholics. <i>Addiction</i> , 1989, 84, 97-102.	3.3	27
167	Clinical pharmacology of anxiolytics and antidepressants: A psychopharmacological perspective. , 1989, 44, 309-334.		66
168	Rapid cycling affective disorders in the mentally retarded. <i>Biological Psychiatry</i> , 1989, 26, 250-256.	1.3	51
169	Monoamine Oxidase Inhibitors: Rehabilitation from Recent Research?. <i>British Journal of Psychiatry</i> , 1989, 154, 287-291.	2.8	40
170	Aspects of alpha-2-adrenoceptor function in normal volunteers. <i>Human Psychopharmacology</i> , 1988, 3, 235-245.	1.5	12
171	The hypothermic response to clonidine is absent in alcohol withdrawal but returns in abstinence. <i>Biological Psychiatry</i> , 1988, 24, 102-104.	1.3	17
172	Psychopathology in Adult Mentally Handicapped Hospital Patients. <i>Australian and New Zealand Journal of Psychiatry</i> , 1988, 22, 312-315.	2.3	7
173	Clonidine challenge testing of alpha-2-adrenoceptor function in man: the effects of mental illness and psychotropic medication. <i>Journal of Psychopharmacology</i> , 1988, 2, 119-137.	4.0	21
174	alpha-2-Adrenoceptor Function in Alcohol Withdrawal: A Pilot Study of the Effects of IV Clonidine in Alcoholics and Normals. <i>Alcoholism: Clinical and Experimental Research</i> , 1988, 12, 14-18.	2.4	61
175	Psychotherapy and Dysmorphophobia: A Case Report. <i>British Journal of Psychiatry</i> , 1988, 152, 271-274.	2.8	32
176	Platelet Monamine Receptor Binding in Alcoholics During Withdrawal. <i>Addiction</i> , 1987, 82, 1253-1255.	3.3	4
177	Clonidine in alcohol withdrawal: a pilot study of differential symptom responses following i.v. clonidine. <i>Alcohol and Alcoholism</i> , 1987, 22, 161-6.	1.6	9
178	Monoamines and Alcohol. <i>Addiction</i> , 1986, 81, 327-338.	3.3	41
179	Benzodiazepines for generalised anxiety disorder (GAD). <i>The Cochrane Library</i> , 0, , .	2.8	0
180	Right Frontal Theta: Is It a Response Biomarker for Ketamine's Therapeutic Action in Anxiety Disorders?. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	0